Enoxaparin sodium 40mg PFS
| Product Overview | |
| Generic Name | Enoxaparin sodium 40mg PFS |
| Brand Name(s) | Lovenox, Clexane, Xaparin |
| Form | PFS, Subcutaneous or Intravenous |
| Strength | 40 mg/0.4mL |
| Therapeutic Class | Antithrombotic agent: |
| ATC Code | B01AB05 |
| Manufacturing & Regulatory | |
| Manufacturer | Sanofi, Other Biosimilar mfgs |
| Country | India/USA/EU |
| GMP Compliance | WHO-GMP |
| DMF/CEP | Manufacturer-specific, not public |
| COFEPRIS | Under Registration (2025) |
| Free Sale Certificate | Available per batch upon request |
| Logistics & Export | |
| MOQ | 10 Units |
| Shelf Life | 36 months |
| Storage | Store at 20–25 °C |
| Incoterms | EXW/FOB/CIF negotiable |
| Lead Time | 7 - 10 Business Days |
| Documentation | |
| Certificate of Analysis (COA) | Supplied per batch upon request |
| SDS | Manufacturer provides standard SDS (biologic/aqueous injectable) |
| CTD Summary | CTD available to regulators; summary available to qualified partners |
Description
Indications & Usage: Enoxaparin sodium is indicated for prophylaxis and treatment of venous thromboembolism (DVT/PE), unstable angina, non‑ST elevation myocardial infarction, perioperative prophylaxis (hip/knee/abdominal surgery), prevention of clotting during hemodialysis. Acts by potentiating antithrombin III to inhibit factor Xa (and IIa); predictable pharmacokinetics; reversal partial with protamine sulfate
